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Abstract 
Compared  with  other  diagnostic  methods,  ultrasound  is  proven  to  be  a  safe,  simple, 
non-invasive and cost-effective imaging technique, but the resolution is not comparable to that 
of magnetic resonance imaging (MRI). Contrast-enhanced ultrasound employing microbubbles 
can gain a better resolution and is now widely used to diagnose a number of diseases in the 
clinic. For the last decade, microbubbles have been widely used as ultrasound contrast agents, 
drug delivery systems and nucleic acid transfection tools. However, microbubbles are not 
fairly stable enough in some conditions and are not well administrated distributed in the 
circulation system. On the other hand, magnetic nanoparticles, as MRI contrast agents, can 
non-specifically penetrate into normal tissues because of their relatively small sizes. By taking 
advantage of these two kinds of agents, the magnetic microbubbles which couple magnetic 
iron oxides nanoparticles in the microbubble structure have been explored. The stability of 
microbubbles can be raised by encapsulating magnetic nanoparticles into the bubble shells and 
with the guidance of magnetic field, magnetic microbubbles can be delivered to regions of 
interest, and after appropriate ultrasound exposure, the nanoparticles can be released to the 
desired area while the magnetic microbubbles collapse. In this review, we summarize magnetic 
microbubbles used in diagnostic and therapeutic fields, and predict the potential applications 
of magnetic microbubbles in the future. 
Key words: Magnetic microbubble; Dual-modality imaging; Drug delivery system; Molecular im-
aging. 
1. Introduction 
Among  all  the  diagnostic  imaging  techniques, 
ultrasound imaging has a unique advantage because 
of its features of real-time, low-cost, high safety, and 
ease of incorporation into portable devices. By using 
the  ultrasound  contrast  agents,  the  resolution  and 
sensitivity of clinical ultrasound imaging have been 
greatly  improved  [1-3].  Gas  filled  microbubbles  en-
capsulated with the polymer, lipid or surfactant shells 
have  been  well  established  for  the  last  decade.  Be-
cause of their high compressibility, microbubbles can 
be used as the most effective contrast agent for ultra-
sound  imaging  [4,  5].  Moreover,  with  the  use  of 
sonoporation  [6-8],  microbubbles  are  also  becoming 
widely  used  as  drug  delivery  systems  and  nucleic 
acid transfection tool [9-12]. However, the transfection 
efficiency  is  limited  by  ultrasound  intensity.  As  an 
imaging  tool,  the  imaging  quality  of  ultrasound  is 
suboptimal with contrast lower than that of computer 
tomography  (CT)  or  magnetic  resonance  imaging 
(MRI) [13-16].  
On the other hand, MRI is another imaging tool 
which  is  non-invasive  and  capable  of  providing 
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morphological and functional information with a high 
spatial  resolution  and  excellent  soft-tissue  contrast 
[17]. Magnetic nanoparticles can be used as powerful 
contrast agents for MRI [18, 19]. Especially, magnetic 
iron  oxide  nanoparticles  with  superparamagnetic 
property have also shown potential as multifunctional 
nanoparticles for clinical translation besides they have 
been used as MRI constrast agents in clinic because 
their  features  could  be  easily  tailored  by  including 
targeting  moieties,  fluorescence  dyes,  therapeutic 
agents or agents. For example, they can also be used 
as potential anti-cancer agents for their cytotoxicity, 
genotoxicty and hyperthermia [20-22]. 
The combination of microbubbles and magnetic 
nanoparticles, that is, the magnetic microbubbles can 
make  use  of  the  disadvantages  of  microbubbles  or 
magnetic  nanoparticles  respectively:  the  stability  of 
microbubbles  can  be  improved  by  embedded  mag-
netic nanoparticles into the bubble shells [23], mean-
while, the embedded nanoparticles can be delivered 
into  desired  regions  with  the  guidance  of  magnetic 
field and can be released when choosing appropriate 
ultrasound  exposure  [24, 25].  Because  microbubbles 
are  ultrasound  contrast  agents  and  magnetic  nano-
particles are good contrast agents for MRI, magnetic 
microbubbles also can potentially be used as contrast 
agents for both ultrasound imaging and MRI [17, 23, 
26, 27]. With the help of magnetic force, magnetic mi-
crobubbles with specific targeting molecules can bind 
to  microvasculature  more  efficiently  than  nonmag-
netic microbubbles, which make magnetic microbub-
bles a good alternative to nonmagnetic microbubbles 
for vascular molecular imaging [28-30]. 
2. Preparation of magnetic microbubbles 
Gas-filled  and  polymer/lipid/surfactant  en-
capsulated microbubbles have been well established 
in the last 20-30 years. They can be prepared by vari-
ous methods, such as sonication [31-33], high shear 
emulsification [34, 35], membrane emulsification [36, 
37], ink jet printing [38], electrohydrodynamic atom-
ization [39, 40] and microfluidic processing [41-44]. 
Stride and Edirisinghe [14] summarized the tra-
ditional  and  newly  emerging  techniques  to  prepare 
microbubbles and compared the differences of these 
techniques.  The  preparation  of  magnetic  microbub-
bles  is  similar  to  microbubble  preparation  methods 
but with the addition of magnetic nanoparticles. Fig. 1 
shows  the  different  microbubble  constructs  with 
magnetic nanoparticles [45]. Fig. 1(A) shows the con-
struct that magnetic nanoparticles are coupled to the 
shell surface of the microbubble through certain che-
lating agent or electrostatic coupling. Fig. 1(B) shows 
the  structure  that  iron  oxide  nanoparticles  are  em-
bedded  in  the  microbubble  shell.  And  in  Fig.  1(C) 
nanoparticles  are  embedded  in  the  oil  layer  of  the 
microbubble.  
 
 
Figure 1. Schematic diagram of different magnetic microbubble constructs [45]. A. magnetic nanoparticles are coupled to 
the shell surface of the microbubble. B. iron oxide nanoparticles are embedded in the microbubble shell. C. nanoparticles are 
embedded in the oil layer of the microbubble. Theranostics 2012, 2(1) 
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Figure 2. Schematics of two different magnetic microbubbles [25, 23] 
 
 
Fig. 2(A) shows an entity of Fig. 1(A) generated 
by electrostatic coupling [25]. Soetanto et al. covered 
magnetite particles with an anionic surfactant to make 
them negatively charged and their self-made surfac-
tant  microbubbles  were  also  negatively  charged.  In 
the end they use calcium ions as multivalent anions to 
connect the magnetites to the surface of the surfactant 
microbubbles. Actually, in order to obtain magnetic 
microbubbles with nanoparticles coupled to the sur-
face of the shell, one can also use microfluidic devices, 
the coupling process is much easier [13]. For example, 
Park et al. mixed an aqueous solution containing an-
ionic Fe3O4 nanoparticles, lysozyme and alginate with 
CO2 gas to the three channels through syringe pumps 
to form stable functionalized magnetic microbubbles 
in  a  narrow  size  distribution  (Fig.  3(A)).To  entrap 
magnetic nanoparticles into oil layer (inner layer) of a 
double-layered  microbbuble  (Fig.  1(C)),  Yang  et  al. 
[23]  used  a  double  solvent  evaporation  interfacial 
deposition  process  (double-emulsion  procedure)  to 
prepare magnetic  microbubbles which have a poly-
mer shell with superparamagnetic iron oxide (SPIO) 
nanoparticles  embedded  inside  (Fig.  2(B)).  The  pre-
pared magnetic microbubbles have a mean diameter 
of 3.98 μm with polydispersity index of 0.425. Chow et 
al. [27] used a similar method (Fig. 3(C)) to prepare 
MION-entrapped PMBs (monocrystalline iron oxide 
nanoparticles-entrapped polymer microbubbles).  
Liu et al. [17] used one-pot emulsion polymeri-
zation to embed iron oxide nanoparticles into the mi-
crobubble shells (Fig. 3(B)), this is a living example as 
showed in Fig. 1(B). They used a syringe to add butyl 
cyanoacrylate (BCA) into freshly prepared ultrasmall 
superparamagnetic iron oxide (USPIO) solution, and 
then agitated the mixture at a high speed (1000 rpm) 
at room temperature. Then they collected the upper 
solid foam after 4 days. At last they washed out the 
impurities  with  Triton  X-100  and  centrifuged  the 
UPMB (USPIO-PBCA microbubble, that is ultrasmall 
superparamagnetic iron oxide-poly(butyl cyanoacry-
late) microbubble) suspension to collect the superna-
tant bubble-cake. After ultrasound exposure, the iron 
oxide nanoparticles inside the microbubble shells are 
released out. 
In a word, it’s hard to say which one of the pre-
sent methods is the best to prepare stable, monodis-
persed magnetic microbubbles because each method 
has  its  advantages  and  disadvantages  respectively. 
Based on the present methods, in order to obtain the 
better size distribution, the cost of the processing in-
evitably would be increased because of the low yield. 
Therefore, specific preparation methods are employed 
to meet corresponding needs. And the development 
of novel preparation methods is also still attracting in 
the future research. 
3. Magnetic microbubbles as imaging con-
trast agents (diagnostic) 
3.1. Dual modality imaging contrast agents 
Although  ultrasound  imaging  is  a  safe  and 
non-invasive  imaging  technique  in  the  diagnostic 
field, the signal is usually disturbed by many factors. 
The ability of ultrasound to reveal the tissue structure 
is worse than that of CT and MRI. So it’s a good op-
tion to combine US imaging with other imaging mo-
dalities,  such  as  MRI.  Magnetic  microbubbles  can 
make this formulation come true. The magnetic na-
noparticles embedded in the bubbles can be excellent 
contrast agents for MRI. On the other hand, the mi-
crobubbles are proven to be good contrast agents for 
ultrasound  imaging.  Furthermore,  gas-filled  mi-
crobubbles can potentially be used as an intravascular 
MR susceptibility contrast agent in vivo because of the 
induction  of  large  local  magnetic  susceptibility  dif-
ference  by  the  gas-liquid  interface.  The  dual-mode 
imaging  could  offer  more  valuable  information  to Theranostics 2012, 2(1) 
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make  more  accurate  diagnosis  than  either  modality 
alone. In MRI, the magnetic field can also guide the 
magnetic  microbubbles  to  the  specific  locations, 
making the imaging more efficient. 
 
 
Figure 3. Schematic illustrations of three different procedures [13, 17, 27]. A: micro fluidic device: membrane materials, 
nanoparticle solution and the gas are pumped into the micro tubes to form magnetic microbubbles through electrostatic 
coupling; B: one-pot emulsion polymerization: consisting of the emulsion polymerization of BCA and the encapsulation of 
USPIO; C: double-emulsion: consisting of the forming of a water/oil emulsion and (water/oil)/water emulsion, and lyophi-
lization to entrap MION into the oil layer of the bubble shell. Theranostics 2012, 2(1) 
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The magnetic microbubbles that Yang et al. [23] 
prepared  are  Fe3O4-inclusion  PLA-PVA  (poly 
(DL-lactide)-polyvinyl  alcohol)  double-layered  mi-
crobubbles. They embedded various concentrations of 
Fe3O4  nanoparticles  in  the  oil  layer  of  the  constant 
shell. Compared with non-SPIO-inclusion microbub-
bles,  the  transverse  relaxation  rate  (R2)  of 
SPIO-inclusion microbubbles increases more rapidly 
with  the  increase  of  microbubble  volume  fraction. 
When  the  microbubble  volume  fraction  reaches 
greater than 60%, the SPIO-inclusion EMB (encapsu-
lated  microbubble)  solution  can  enhance  transverse 
relaxivity  significantly.  This  result  indicates  that 
SPIO-inclusion EMBs can act better in MRI compared 
with non-SPIO-inclusion microbubbles. As for ultra-
sound imaging, SPIO-inclusion microbubbles enhance 
the  image  contrast  significantly  compared  with 
non-SPIO-inclusion microbubbles. On the other hand, 
with the increase of the inclusion concentration, the 
enhance ability of SPIO-inclusion EMBs increased first 
and decreased later, animal experiments verified the 
results. 
Similar phenomena were observed in the case of 
Liu’s  research  [17]  in  which  the  USPIOs  were  en-
trapped  in  the  hard  shell  of  the  microbubble.  They 
used US-MR phantom imaging assay to determine the 
acoustic and magnetic properties of the microbubbles. 
Compared  with  pure  microbubbles,  UPMBs 
(USPIO-PBCA  microbubbles)  generated  comparable 
signals both in ultrasound imaging and MRI. When 
the magnetic nanoparticles are coupled to the surface 
of the microbubble [13], they can also increase the T2 
relaxation rate of the water near the ROI (region of 
interest) to enhance the negative signal. 
The  above  results  indicate  that  no  matter  the 
magnetic nanoparticles are coupling to the surface of 
the microbubble shell, entrapped in the shell or em-
bedded in the inner layer of the microbubble shell, the 
magnetic microbubbles can highly enhance both ul-
trasound  imaging  contrast  and  MRI  contrast  [3,  13, 
17]. 
Of  all  the  three  described  examples,  when  the 
concentration of the magnetic nanoparticles rises, the 
enhancing ability of magnetic microbubbles increases 
first  and  then  decreases  in  MRI,  and  the  extremely 
high embedded magnetic nanoparticle concentration 
results in relatively low ultrasound contrast intensity. 
The  explanation  to  the  phenomenon  is  that  the  ex-
tremely  high  concentration  embedded  magnetic  na-
noparticles  could  hinder  the  oscillation  of  the  mi-
crobubbles. According to the above research results, 
we can choose moderate magnetic nanoparticle con-
centration of magnetic microbubbles to gain the best 
US & MR imaging efficacy, for example in the refer-
ence  23,  the  moderate  concentration  may  be  set  at 
80%. 
Furthermore,  microbubbles  can  potentially  be 
used  as  an  intravascular  MR  susceptibility  contrast 
agent in vivo because of the induction of large local 
magnetic  susceptibility  difference  by  the  gas-liquid 
interface [26]. The magnetic susceptibility of the mi-
crobubbles  locally  perturb  the  static  magnetic  field, 
which influences the transverse-relaxation properties 
of the surrounding medium. Changes in the pressure 
after the bubble dimensions affect the magnetic field 
perturbations and subsequently the transverse relax-
ation.  But  compared  with  other  intravascular  MR 
susceptibility contrast agents, the susceptibility effect 
of microbubbles is relatively weak. Chow et al. [27] 
found  that  by  entrapping  MIONs  into  PMB  shells 
could enhance the microbubble susceptibility, hence, 
the  magnetic  microbubbles  can  serve  as  a  good  in-
travascular  MR  contrast  agent  and  blood  pressure 
sensor. 
But here comes a problem: How to form a kind 
of magnetic microbubbles to gain the strongest intra-
vascular MR susceptibility? Dharmakumar et al. [45] 
resolved this problem through analytical approxima-
tions  and  numerical  simulations.  They  used  fi-
nite-element simulations to demonstrate that the ef-
fective volumetric magnetic susceptibility of a coated 
microbubble  is  dependent  on  the  radius,  the  shell 
volume fraction and the magnetic susceptibility of the 
particulates  on  the  shell.  The  results  suggest  that  a 
suitable  microbubble  formulation  which  will  be 
MR-sensitive to small pressure changes at 1.5 T must 
be  2-3  μm  in  radius  and  be  uniformly  coated  with 
single-domain magnetic nanoparticles, and the shell 
volume fractions should be below 5%, which means 
the magnetic microbubble shells should be very thin. 
Actually  most  lipid-encapsulated  and  surfac-
tant-encapsulated  microbubbles  are  up  to  the  mus-
tard. 
 In  a  word,  dual  modality  imaging  for  ultra-
sound and magnetic resonance imaging is the main 
application of magnetic microbubbles. The key factors 
that influence the dual modality imaging quality of 
magnetic microbubbles are the stability of micobub-
bles  and  the  viscosity  of  the  bubble  membrane.  To 
obtain  images  of  good  quality,  we  should  choose 
proper membrane materials (polymers, lipids or sur-
factants)  and  moderate  magnetic  nanoparticle  con-
centration to form magnetic microbubbles for better 
clinical applications. 
3.2. Molecular imaging contrast agents 
Angiogenesis  is  the  normal  physiological  pro-
cess for newblood vessels to develop from preexisting Theranostics 2012, 2(1) 
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ones, it is a keystone in the treatment of cancer and 
potentially  many  other  diseases,  such  as  cardiovas-
cular diseases. With the introduction of microbubbles 
that can be targeted to the molecular markers related 
to  angiogenesis  (VEGFR-2,  integrin  αvβ3,  and  en-
doglin), ultrasound imaging has become an attractive 
imaging modality to non-invasively assess tumor an-
giogenesis. 
 
 
 
 
 
Figure  4. The schematic of molecular imaging with tar-
geted ultrasound contrast agents [47]. 
 
 
Molecular  imaging  with  targeted  ultrasound 
contrast agents (Fig. 4) can be illustrated as the fol-
lowing: A specific ligand, which can bind to the re-
ceptor of interest, is attached to the shell of a gas-filled 
microbubble. The resulting targeted contrast material 
circulates  for  a  period  of  time,  and  is  gradually 
cleared. At the same time, targeting occurs due to the 
specific ligand-receptor interaction, and some of the 
microbubbles which had a chance to flow through the 
target area are selectively attached to the receptor. The 
area  with  high  level  contrast  marks  the  recep-
tor/disease site and can be imaged [47].  
However, traditional imaging methods act well 
in atherosclerosis, angiogenesis and inflammation of 
microvasculature but not larger vessels (such as aorta) 
due to the high flow speed of the blood in larger ves-
sels (high shear stress) [4-5]. Molecular imaging with 
magnetic  microbubbles  may  resolve  this  difficulty: 
with  the  guidance  of  the  magnetic  field,  magnetic 
microbubbles can accumulate in the region of interest, 
the targeting molecular markers then can specifically 
attach to the tissue or cells to offer a real-time, non-
invasive visualization at the molecular level.To make 
it possible to enhance the ultrasound molecular im-
aging efficiency of atherosclerosis in the aorta, Wu et 
al. [28] prepared magnetic microbubbles conjugated 
with anti-VCAM (vascular cell adhesion molecule)-1 
antibodies (Fig. 5) to enhance the molecular imaging 
efficiency of atherosclerosis.  
 
 
 
Figure 5. Illustration of microbubble axial flow behavior and magnetic field-guided targeting [28]. 
 Theranostics 2012, 2(1) 
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This kind of magnetic microbubbles can easily 
target to VACM-1, with the introduction of magnetic 
field, the microbubbles can accumulate in the specific 
vascular areas.  
Three  kinds  of  microbubbles  are  made:  the 
magnetic VCAM-1-targeted microbubbles (MVMBs), 
the  untargeted  magnetic  microbubbles  (MMBs)  and 
the  nonmagnetic  VCAM-1-targeted  microbubbles 
(VMBs). The results showed that MVMBs attached to 
the VCAM-1-Fc (Fc section of anti-VCAM-1 antibody) 
coated plates just like VMBs in the absence of mag-
netic field guidance, but when the magnetic field was 
introduced, attachment of MVMBs was significantly 
higher  than  that  of  VMBs.  Animal  experiments 
showed outstanding attachment to aorta of the mag-
netic  microbubbles  and  the  microbubbles  were  dis-
tributed throughout the aorta. US imaging of athero-
sclerosis guided by magnetic field showed significant 
diversity. The mean video intensity of MVMBs was 
the strongest, followed by the VMBs, the lowest video 
intensity was for the MMBs. After 5-minute flush, the 
three  kinds  of  microbubbles  in  wild-type  mice 
(healthy mice without atherosclerosis) showed similar 
video intensity, while the magnetic microbubbles of 
experimental  sets  (apolipoprotein  E-deficient  mice) 
still remained significant video intensity.  
This  result  means  the  anti-VCAM-1  antibody 
coated magnetic microbubbles can efficiently attach to 
the inner wall of aorta even at a very high shear stress, 
resulting in improved detection of the early stages of 
atherosclerosis, which makes them excellent athero-
sclerosis imaging contrast agents. They also used bio-
tinylated anti-mice P-selectin (MBpm) to replace the 
anti-VCAM-1 antibody to form a similar type of mi-
crobubbles which can attach to endothelial P-selectin, 
making  the  magnetic  microbubbles  to  be  excellent 
magnetic  guided  inflammatory  molecular  imaging 
contrast agents in high-shear flow [29]. 
The  main  advantage  of  antibodies  modified 
magnetic microbubbles to be vascular molecular im-
aging contrast agents is that with the magnetic field 
guiding  to  the  specific  location  and  the  binding  of 
specific molecules to the endothelial cells, the double 
attraction forces (the magnetic force and the binding 
force  of  the  coupled  molecules)  make  the  magnetic 
microbubbles attached to the vascular firmly even in a 
high shear stress, while the situation of non-magnetic 
microbubbles things is quite different. 
4. Magnetic microbubbles for drug delivery 
(therapeutic) 
To minimize drug degradation and loss, to pre-
vent harmful side-effects and to increase drug bioa-
vailability and the fraction of the drug accumulated in 
the  required  zone,  various  drug  delivery  and  drug 
targeting systems are currently developed or under 
development [48-50].  
4.1. Drug delivery systems 
Microbubble can be a good type of drug delivery 
system due to the phenomenon called sonoporation: 
Cell membranes can become temporarily “open”  to 
small and large molecules and then “resealed” when 
relatively low amplitude  ultrasound is applied to a 
cell suspension that contains an ultrasound contrast 
agent.  Consequently,  foreign  molecules  may  be 
trapped in the cells. [6-8]. If we trap drugs inside the 
microbubbles, with the sonopoartion, the drugs will 
be released out of the microbubbles, and then swal-
lowed  by  the  temporally  opened  cells  and  trapped 
inside  them.  Magnetic  microbubbles  are  especially 
outstanding  drug  delivery  systems  of  microbub-
ble-type drug delivery systems because they can be 
guided by the magnetic field to the specific locations 
of interest. 
Fe3O4-inclusion microbubbles can be used as in 
situ drug delivery systems other than dual-modality 
contrast agents for ultrasound imaging and MRI [24]. 
When  a  focused  ultrasound  is  introduced  to  a  cell 
solution  with  the  presence  of  Fe3O4-inclusion  mi-
crobubbles, sonoporation occurs. Then the microbub-
bles  can  be  destroyed,  consequently  the  embedded 
Fe3O4 nanoparticles will be released from the shells of 
the  microbubbles,  at  this  moment  the  transiently 
opened cells can adopt the nanoparticles, which will 
result in a series of bioeffects on the cells. Yang et al. 
studied the delivery efficiency of the Fe3O4 nanopar-
ticles and other bioeffects. They found that the Fe3O4 
nanoparticles embedded in the shells of microbubbles 
can be delivered into the tumor cells, and the delivery 
rate increases as the acoustic intensity increases. The 
entered Fe3O4 nanoparticles possessed a suitable cy-
totoxicity, the cell apoptosis increases as the acoustic 
intensity  increases.  Compared  with 
non-Fe3O4-inclusion  microbubbles,  the  Fe3O4- 
embedded  microbubbles  have  lower  bioeffects  be-
cause  the  embedded  nanoparticles  enhance  the  sta-
bility of the microbubbles, and subsequently hinder 
the oscillation of the microbubbles. 
When the Fe3O4 nanoparticles are delivered into 
cells,  they  can  cause  an  effect  called  hyperthermia 
with an alternating magnetic field introduced, causing 
corresponding cell damage. Although this work is not 
strictly  a  drug  delivery  case  as  it  only  delivers  the 
nanoparticles inside the bubble shell to tumor cells, 
not  the  specific  drugs,  the  Fe3O4  nanoparticles  can 
serve as hyperthermia agents in some conditions. We 
can also predict that if we filled the Fe3O4-inclusion Theranostics 2012, 2(1) 
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microbubbles with specific drugs, for example, dox-
orubicin  (a  tumor  suppression  drug),  we  can  effec-
tively delivery the drug to tumor tissue with magnetic 
field guiding. 
4.2. Gene transfection systems 
If we replace drugs with nucleic acids, drug de-
livery  systems  described  above  can  become  gene 
transfection  systems.  Of  many  gene  transfection 
models, magnetic targeting and ultrasound -enhanced 
delivery is gaining more and more attention. 
Vlaskou et al. [51] formed magnetic microbub-
bles  through  self-assembly  of  the  lipids,  magnetic 
nanoparticles  and  nucleic  acids  (Fig.  6).  They  used 
three  different  types  of  nucleic  acids  (the  luciferase 
reporter gene in NIH3T3 mouse fibroblasts, in H441 
human lung epithelial cells and luciferase siRNA) to 
study  the  delivery  efficiency  in  cultured  adherent 
cells, the results showed that when a magnetic field 
was applied, efficient delivery of these nucleic acids’ 
delivery  was  achieved  and  it  was  comparable  with 
commercially  available  transfection  reagents 
(SONOVUE microbubbles). And the transfection effi-
ciency  was  much  higher  than  when  using  plasmid 
applied with SONOVUE microbubbles (one kind of 
commercially  available  lipid  microbubbles)  and  ul-
trasound. Combined use of ultrasound and the mag-
netic field didn’t further enhance the transfection ef-
ficiency. The in vivo experiments in mice showed that 
when a magnetic field was introduced to the mouse 
chest, the accumulation of plasmid DNA in the tar-
geted site would be two to three fold of the untargeted 
site in the lungs. They used the similar formulation to 
transfer a report gene to HeLa cells, the cells treated 
with  the  microbubbles  and  ultrasound  expressed  a 
dose-dependent  cytotoxicity.  This  formulation  of 
magnetic microbubbles can be a promising gene de-
livery vector and cancer gene therapy reagent.  
Since the genes can be coupled or entrapped to 
the magnetic microbubbles, the gene delivery process 
becomes controllable and visible by the guidance of 
the  dual-modality  imaging.  Based  on  the  magnetic 
microbubble,  the  gene  delivery  system  may  have 
more promising applications. 
 
 
Figure 6. Schematic of the self-assembly of the lipids, MNPs, and nucleic acids into magnetic microbubbles and the animal 
experiment setting [51]. 
 
 
5. Conclusion and perspective 
Although  the  magnetic  microbubbles  play  an 
important role in preclinical diagnostic and therapeu-
tic fields due to their excellent properties to be dual 
modal contrast agents for US imaging and MRI, drug 
delivery systems, nucleic acid delivery systems and 
molecular  imaging  contrast  agents,  present  studies 
are  still  limited  to  simulated  researches,  cell  re-
searches and small animal studies [30]. Future work of 
magnetic microbubbles could be focused on the de-
velopment  of  multi-modal  imaging  contrast  agents, 
accurate administration of drug/gene delivery system 
and clinical translation. 
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